BMC Biology is calling for submissions on the topic of Stem cells and cancer, that explores the intricate relationship between stem-cell and cancer biology. In particular, we welcome studies providing new insights on the characterization and regulation of cancer stem cells, the role of stem and progenitor cells of the niche in the propagation of the tumor, and the role of reprogramming in this context, as well as potential therapeutic strategies based on reprogramming or targeting of various stem and progenitor cells. Moreover, studies describing the use of induced pluripotent stem cells for cancer modeling and as a drug discovery platform will also be considered, as well as studies on the use of stem cells homing to deliver targeted therapy to tumors.
Submit your manuscript to this collection through the participating journal.
-
Jianhai Jiang
Dr Jiang Jianhai received his PhD in biochemistry and molecular biology from Fudan University in 2007 and the title of Professor from Fudan University in 2013. Dr Jiang has long been engaged in the study of the glycobiology of cancer stem cells. His group systematically explored the function and mechanism of N-glycan and the cancer stem cell marker CD133 in cancer development. Till now, Dr Jiang has published more than 10 papers as a corresponding author in PNAS, J. Biol. Chem. J. Hepatol, Cell Reports, and Advanced Science. -
Charles K. Kaufman
Dr Kaufman's clinical and research interests focus on transcriptional and epigenetic mechanisms of cell-type-specific gene regulation, both in normal cells like keratinocytes and melanocytes as well as in cancerous melanoma cells. As a practicing oncologist treating skin cancer patients, he also seeks to synthesize ideas from the lab and clinic with the goal of discovering new therapeutic targets in melanoma. -
Hernando Lopez-Bertoni
Dr Bertoni's research aims to understand the molecular mechanisms involved in regulating stemness and differentiation in neoplastic and non-neoplastic neural cells. Specifically, he is interested in better understanding Glioblastoma Multiforme (GBM) by studying the molecular mechanism by which these cells acquire a stem-like phenotype and using this knowledge to develop new ways to treat and diagnose the disease. He intends to find miRNAs and tumor suppressive pathways that can limit GBM stem-like tumor-propagating behaviors and use that information to develop novel treatment methods. -
Ander Matheu
Dr Matheu is Head of the Cellular Oncology group in the Oncology Department at the Biogipuzkoa Health Research Institute. His have always focused on cancer and aging research. Specifically, he is interested in understanding the molecular mechanisms underlying stem cell deregulation in both processes. Decline in aging and activation of cancer. In the latter, the group is focused on characterizing the impact of cell heterogeneity in tumor initiation and maintenance in several cancer types, including brain and gastrointestinal cancers, as well as cell plasticity in advanced stages of cancer progression, metastasis, and therapy resistance.